Skip to content

Released Nov 5, 2025, before the open

10-Q filed Nov 5, 2025, 36 days after period end · 0001171843-25-007005

Q3 2025 · 10-Q
Revenue$0.00— vs Q3 2024no prior Q2 2025 on file
Net Income-$14.26MN/M vs Q3 2024N/M vs Q2 2025
EPS, diluted—
Operating Income-$15,817,000N/M
Operating Cash Flowderived-$10,849,000N/M
Free Cash Flowderived-$10,856,000N/M

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$0.00$0.00$0.00—
Net Income-$14.26M-$10.48M-$9.96M-$11.98M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR